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£87 k during 2002–2005. Using RCT data rather than GPRD
data for event probabilities, the mean cost was £8 k with the
VIGOR RCT and £10 k with the CLASS RCT. CONCLUSIONS:
The published cost-effectiveness analyses of coxibs lacked exter-
nal validity and did not represent patients in actual clinical
practice. External validity should be an explicit requirement in
cost-effectiveness analyses.
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OBJECTIVES: Notwithstanding evidence showing its clinical
effectiveness, little if any data have supported the cost-
effectiveness of psychosocial interventions for patients with
ADHD. The NIMH-initiated MTA study was designed to maxi-
mize clinical effectiveness of psychosocial interventions in chil-
dren with ADHD. We use patient-level data from this study to
estimate the maximum allowable cost of better-targeted behav-
ioral interventions that would still meet currently used bench-
marks for cost-effectiveness in Europe, assuming they replicate
clinical effectiveness as reported in the MTA study. METHODS:
A total of 579 children age 7–9.9 years with ADHD (DSM-IV)
were randomly assigned medication management (MedMgt),
intense behavioral treatment (Beh), both combined (Comb), or
community care (CC). All MTA treatment strategies were clini-
cally effective. Costing from a societal and from a third-party
payer’s perspective for Germany, The Netherlands, Sweden, and
UK excluded the research component of the study. Treatment
response was deﬁned as normalization of core symptoms after 14
months. QALYs were estimated using utility weights derived
from UK expert and parent-proxy-ratings. Comb was most effec-
tive, and Med dominated Beh economically. Using this data, we
estimated the maximum allowable cost (MAC) of Comb versus
Med, quantifying the uncertainty by means of non-parametric
bootstrapping. RESULTS: MACs and their 95% conﬁdence
intervals for Comb versus Med were determined (a) for ADHD,
and for subgroups with (b) “pure” ADHD (without comorbidity,
n = 184) and (c) hyperkinetic disorder (HKD, with or without
conduct disorder, n = 145), assuming (1) Comb meeting an ICER
threshold (when added to MedMgt) of (1) €50,000 or (2)
€100,000 per QALY. MACs for UK were (1) €2943 (€2569–
€3310) and (2) €3328 (€2612–€4043). Estimates for Germany
and The The Netherlands were lower, whereas Swedish estimates
were broadly in line with UK data. CONCLUSIONS: Despite
some limitations, which will be discussed, these estimates may
assist designing clinical studies to support acceptable cost-
effectiveness of psychosocial treatment strategies for ADHD.
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OBJECTIVES: To determine the percentage of patients who had
a continued diagnosis of attention-deﬁcit hyperactivity disorder
(ADHD) from childhood to adulthood in real practice and to
examine the association between the sustained diagnosis of
ADHD, other mental health comorbidities and the exposure to
psychotropic medications. METHODS: A retrospective longitu-
dinal analysis was conducted using the 1995 to 2001 Medicaid
claims data. The study cohort were patients 4–17 years of age
who received a diagnosis of ADHD in the year 1995. These
patients were then followed through 2001 to determine the per-
centage that retained the diagnosis of ADHD. Multivariate
regression analysis was employed to assess the association
between sustained ADHD diagnosis, other mental health
comorbidities (conduct disorder, oppositional deﬁant disorder,
mood disorders, anxiety disorder and substance abuse disorder)
and the exposure to psychotropic medications (stimulants,
antidepressants, antipsychotics, antianxiolytics, anticonvul-
sants). RESULTS: A total of 18,131 patients were identiﬁed with
a diagnosis of ADHD in 1995 and had continuous Medicaid
eligibility during the 7 year follow-up period. Out of those only
10,746(57.77%) retained a diagnosis of ADHD in the ﬁrst year
follow-up and merely 1530 (8.43%) retained the diagnosis of
ADHD in 2001. The length of retaining ADHD diagnosis is
positively associated with the early exposure to stimulants and
having mental health comorbidities such as mood disorders,
anxiety disorder, conduct disorder and oppositional deﬁant dis-
order. CONCLUSIONS: The result is in conﬁrmation with pre-
vious prospective studies which indicated that ADHD shows a
remission with maturation. However, the proportion of patients
retaining ADHD diagnosis in real practice is 60% to 80% lower
than the ﬁndings of those prospective studies, which suggests a
signiﬁcant gap between knowledge advancement and practice.
Further study is needed to clarify the relationship between psy-
chopharmacotherpy and sustained diagnosis of ADHD from
childhood to adulthood.
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OBJECTIVES: To evaluate the cost-effectiveness of methylpheni-
date (MPH)-OROS, a long-acting formulation given once daily
(o.a.d.), compared to short-acting MPH (immediate-release, IR),
which requires twice (b.i.d.) or thrice (t.i.d.) daily administration
schedules, from a payer’s perspective in Finland. METHODS:
Health care resource utilization was estimated based on the
Canadian ADHD RCT by Steele et al. (2006), comparing MPH-
OROS (average dose at study end, 37.8 mg/d; n = 70) with usual
care using MPH-IR (n = 73; hereof, 61% t.i.d., 34.6 mg/d; 39%,
b.i.d., 31.4 mg/d) in an open-label ‘pragmatic’ parallel-group
design over eight weeks. For costing, these data were combined
with Finnish unit costs. Effectiveness was deﬁned as intent-to-
treat remission rates as determined by parent ratings (primary
study endpoint: 18-item SNAP-IV scale). For an estimation of
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